Tocilizumab in Patients with Symptomatic Kaposi sarcoma Herpesvirus (KSHV)- associated Multicentric Castleman disease.

[1]  D. Hammoud,et al.  Emergence of Kaposi’s Sarcoma Herpesvirus-Associated Complications Following Corticosteroid Use in TB-IRIS , 2018, Open forum infectious diseases.

[2]  R. Yarchoan,et al.  HIV‐Associated Cancers and Related Diseases , 2018, The New England journal of medicine.

[3]  R. Yarchoan,et al.  Treatment of Kaposi Sarcoma Herpesvirus-Associated Multicentric Castleman Disease. , 2018, Hematology/oncology clinics of North America.

[4]  D. Pinato,et al.  Relapse of HHV8-positive multicentric Castleman disease following rituximab-based therapy in HIV-positive patients. , 2017, Blood.

[5]  S. Steinberg,et al.  Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease. , 2014, Blood.

[6]  S. Steinberg,et al.  Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. , 2013, Blood.

[7]  W. Klapper,et al.  HHV-8-encoded viral IL-6 collaborates with mouse IL-6 in the development of multicentric Castleman disease in mice. , 2012, Blood.

[8]  S. Steinberg,et al.  High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy. , 2011, Blood.

[9]  M. Bower.  How I treat HIV-associated multicentric Castleman disease. , 2010, Blood.

[10]  M. Hashizume,et al.  Influence of humanized anti-IL-6R antibody, tocilizumab on the activity of soluble gp130, natural inhibitor of IL-6 signaling , 2009, Rheumatology International.

[11]  S. Montoto,et al.  Brief Communication: Rituximab in HIV-Associated Multicentric Castleman Disease , 2007, Annals of Internal Medicine.

[12]  S. Montoto,et al.  Rituximab as retreatment for rituximab pretreated HIV-associated multicentric Castleman disease. , 2007, Blood.

[13]  É. Oksenhendler,et al.  Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  L. Staudt,et al.  Clinical Trials and Observations , 2007 .

[15]  V. Calvez,et al.  Rituximab therapy for HIV-associated Castleman disease. , 2003, Blood.

[16]  T. Kishimoto,et al.  Receptor engagement by viral interleukin-6 encoded by Kaposi sarcoma-associated herpesvirus. , 2001, Blood.

[17]  S. Pittaluga,et al.  Serum viral interleukin-6 in AIDS-related multicentric Castleman disease. , 2001, Blood.

[18]  Y. Chang,et al.  KSHV-encoded viral IL-6 activates multiple human IL-6 signaling pathways. , 1999, Human immunology.

[19]  S. Krown,et al.  Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.